<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Proteogenomics - Detailed Overview</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: Aptos, 'Segoe UI', sans-serif;
            background: white;
            padding: 40px 20px;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 35px 45px;
            background: white;
        }
        
        .title {
            font-size: 28px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 35px;
            text-align: center;
            border-bottom: 3px solid #1E64C8;
            padding-bottom: 15px;
        }
        
        .features-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 15px;
            margin-bottom: 50px;
        }
        
        .feature-card {
            background: #f8fbff;
            border: 2px solid #1E64C8;
            border-radius: 10px;
            padding: 15px 18px;
            transition: all 0.3s;
        }
        
        .feature-card:hover {
            transform: translateY(-3px);
            box-shadow: 0 6px 20px rgba(30, 100, 200, 0.2);
        }
        
        .feature-title {
            font-size: 17px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 8px;
        }
        
        .feature-desc {
            font-size: 16px;
            color: #333;
            line-height: 1.5;
        }

        .detailed-section {
            margin-top: 60px;
        }

        .detail-card {
            margin-bottom: 60px;
            border: 2px solid #e0e0e0;
            border-radius: 15px;
            padding: 30px;
            background: #fafafa;
        }

        .detail-header {
            font-size: 24px;
            font-weight: 700;
            color: #1E64C8;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
        }

        .detail-number {
            background: #1E64C8;
            color: white;
            width: 40px;
            height: 40px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 15px;
            font-size: 20px;
        }

        .diagram-container {
            background: white;
            border: 2px solid #1E64C8;
            border-radius: 10px;
            padding: 25px;
            margin: 25px 0;
            min-height: 250px;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .diagram-svg {
            width: 100%;
            max-width: 800px;
        }

        .description {
            font-size: 16px;
            line-height: 1.8;
            color: #333;
            margin-bottom: 15px;
        }

        .subsection-title {
            font-size: 18px;
            font-weight: 600;
            color: #2563eb;
            margin-top: 20px;
            margin-bottom: 12px;
        }

        .key-points {
            background: #fff;
            border-left: 4px solid #1E64C8;
            padding: 15px 20px;
            margin: 20px 0;
        }

        .key-points ul {
            margin-left: 20px;
        }

        .key-points li {
            margin-bottom: 8px;
            line-height: 1.6;
        }

        .applications {
            background: #e8f4ff;
            border-radius: 8px;
            padding: 20px;
            margin-top: 20px;
        }

        .applications-title {
            font-size: 17px;
            font-weight: 600;
            color: #1E64C8;
            margin-bottom: 10px;
        }

        text {
            font-family: Aptos, 'Segoe UI', sans-serif;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="title">Proteogenomics: Integrating Genomics and Proteomics</div>
        
        <div class="features-grid">
            <div class="feature-card">
                <div class="feature-title">Variant Peptides</div>
                <div class="feature-desc">Protein sequences from genomic variants</div>
            </div>
        
            <div class="feature-card">
                <div class="feature-title">Novel ORFs</div>
                <div class="feature-desc">Discovering new protein-coding regions</div>
            </div>
        
            <div class="feature-card">
                <div class="feature-title">PTM Sites</div>
                <div class="feature-desc">Post-translational modification mapping</div>
            </div>
        
            <div class="feature-card">
                <div class="feature-title">Protein Isoforms</div>
                <div class="feature-desc">Alternative splicing products in proteomics</div>
            </div>
        
            <div class="feature-card">
                <div class="feature-title">Neo-antigens</div>
                <div class="feature-desc">Tumor-specific antigens for immunotherapy</div>
            </div>
        </div>

        <!-- Detailed Sections -->
        <div class="detailed-section">
            
            <!-- 1. Variant Peptides -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">1</div>
                    <span>Variant Peptides</span>
                </div>

                <div class="diagram-container">
                    <svg class="diagram-svg" viewBox="0 0 800 280" xmlns="http://www.w3.org/2000/svg">
                        <!-- DNA Sequence -->
                        <text x="50" y="30" font-size="14" font-weight="bold" fill="#1E64C8">Reference DNA:</text>
                        <rect x="50" y="40" width="700" height="35" fill="#e8f4ff" stroke="#1E64C8" stroke-width="2" rx="5"/>
                        <text x="60" y="62" font-size="16" font-family="monospace" fill="#333">ATG GCC TAT GGC AAA TTC GGA</text>
                        
                        <!-- SNP Arrow -->
                        <path d="M 280 80 L 280 100" stroke="#ff6b6b" stroke-width="3" marker-end="url(#arrowred)"/>
                        <text x="230" y="95" font-size="13" font-weight="bold" fill="#ff6b6b">SNP (T→C)</text>
                        
                        <!-- Variant DNA -->
                        <text x="50" y="125" font-size="14" font-weight="bold" fill="#1E64C8">Variant DNA:</text>
                        <rect x="50" y="135" width="700" height="35" fill="#fff4e6" stroke="#ff9800" stroke-width="2" rx="5"/>
                        <text x="60" y="157" font-size="16" font-family="monospace" fill="#333">ATG GCC </text>
                        <text x="158" y="157" font-size="16" font-family="monospace" fill="#ff6b6b" font-weight="bold">C</text>
                        <text x="173" y="157" font-size="16" font-family="monospace" fill="#333">AT GGC AAA TTC GGA</text>
                        
                        <!-- Proteins -->
                        <text x="50" y="200" font-size="14" font-weight="bold" fill="#1E64C8">Reference Protein:</text>
                        <rect x="50" y="210" width="400" height="30" fill="#d4edda" stroke="#28a745" stroke-width="2" rx="5"/>
                        <text x="60" y="230" font-size="15" font-family="monospace" fill="#333">Met-Ala-Tyr-Gly-Lys-Phe-Gly</text>
                        
                        <text x="50" y="260" font-size="14" font-weight="bold" fill="#ff6b6b">Variant Protein:</text>
                        <rect x="50" y="270" width="400" height="30" fill="#ffe6e6" stroke="#ff6b6b" stroke-width="2" rx="5"/>
                        <text x="60" y="290" font-size="15" font-family="monospace" fill="#333">Met-Ala-</text>
                        <text x="145" y="290" font-size="15" font-family="monospace" fill="#ff6b6b" font-weight="bold">His</text>
                        <text x="177" y="290" font-size="15" font-family="monospace" fill="#333">-Gly-Lys-Phe-Gly</text>
                        
                        <defs>
                            <marker id="arrowred" markerWidth="10" markerHeight="10" refX="5" refY="3" orient="auto" markerUnits="strokeWidth">
                                <path d="M0,0 L0,6 L9,3 z" fill="#ff6b6b" />
                            </marker>
                        </defs>
                    </svg>
                </div>

                <p class="description">
                    Variant peptides represent protein sequences that arise from genomic variations such as single nucleotide polymorphisms (SNPs), insertions, deletions, or other mutations. Proteogenomics allows us to identify these variant peptides by integrating genomic sequencing data with mass spectrometry-based proteomics.
                </p>

                <div class="subsection-title">How It Works:</div>
                <p class="description">
                    Genomic variants identified through DNA or RNA sequencing are used to create customized protein sequence databases. These databases include both reference sequences and variant sequences. Mass spectrometry data is then searched against these expanded databases to identify peptides that match variant sequences rather than the reference genome.
                </p>

                <div class="key-points">
                    <strong>Key Points:</strong>
                    <ul>
                        <li>SNPs can lead to amino acid substitutions, creating variant peptides</li>
                        <li>Indels (insertions/deletions) may cause frameshift mutations</li>
                        <li>Proteogenomics validates genomic predictions at the protein level</li>
                        <li>Essential for personalized medicine and pharmacogenomics</li>
                    </ul>
                </div>

                <div class="applications">
                    <div class="applications-title">Clinical Applications:</div>
                    <ul>
                        <li><strong>Pharmacogenomics:</strong> Understanding how genetic variants affect drug metabolism</li>
                        <li><strong>Disease susceptibility:</strong> Identifying protein variants associated with disease risk</li>
                        <li><strong>Biomarker discovery:</strong> Finding variant peptides as diagnostic markers</li>
                    </ul>
                </div>
            </div>

            <!-- 2. Novel ORFs -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">2</div>
                    <span>Novel Open Reading Frames (ORFs)</span>
                </div>

                <div class="diagram-container">
                    <svg class="diagram-svg" viewBox="0 0 800 300" xmlns="http://www.w3.org/2000/svg">
                        <!-- Genome annotation -->
                        <text x="50" y="25" font-size="14" font-weight="bold" fill="#1E64C8">Conventional Annotation:</text>
                        
                        <!-- Annotated gene -->
                        <rect x="50" y="40" width="700" height="30" fill="#f0f0f0" stroke="#999" stroke-width="1" rx="3"/>
                        <rect x="200" y="40" width="300" height="30" fill="#90ee90" stroke="#28a745" stroke-width="2" rx="3"/>
                        <text x="280" y="60" font-size="13" fill="#333">Known Gene</text>
                        
                        <!-- Ribosome profiling -->
                        <text x="50" y="110" font-size="14" font-weight="bold" fill="#1E64C8">Ribosome Profiling + Mass Spec:</text>
                        
                        <!-- Extended annotation -->
                        <rect x="50" y="125" width="700" height="30" fill="#f0f0f0" stroke="#999" stroke-width="1" rx="3"/>
                        
                        <!-- uORF -->
                        <rect x="80" y="125" width="80" height="30" fill="#ffd700" stroke="#ff9800" stroke-width="2" rx="3"/>
                        <text x="87" y="145" font-size="11" fill="#333">uORF</text>
                        
                        <!-- Main ORF -->
                        <rect x="200" y="125" width="300" height="30" fill="#90ee90" stroke="#28a745" stroke-width="2" rx="3"/>
                        <text x="280" y="145" font-size="13" fill="#333">Known Gene</text>
                        
                        <!-- lncRNA ORF -->
                        <rect x="550" y="125" width="120" height="30" fill="#87ceeb" stroke="#2196F3" stroke-width="2" rx="3"/>
                        <text x="560" y="145" font-size="11" fill="#333">lncRNA ORF</text>
                        
                        <!-- Mass spec evidence -->
                        <g id="peptide1">
                            <path d="M 120 165 L 120 185" stroke="#ff9800" stroke-width="2"/>
                            <circle cx="120" cy="190" r="4" fill="#ff9800"/>
                            <text x="105" y="205" font-size="10" fill="#ff9800">Peptide</text>
                        </g>
                        
                        <g id="peptide2">
                            <path d="M 350 165 L 350 185" stroke="#28a745" stroke-width="2"/>
                            <circle cx="350" cy="190" r="4" fill="#28a745"/>
                            <text x="335" y="205" font-size="10" fill="#28a745">Peptide</text>
                        </g>
                        
                        <g id="peptide3">
                            <path d="M 610 165 L 610 185" stroke="#2196F3" stroke-width="2"/>
                            <circle cx="610" cy="190" r="4" fill="#2196F3"/>
                            <text x="595" y="205" font-size="10" fill="#2196F3">Peptide</text>
                        </g>
                        
                        <!-- Legend -->
                        <text x="50" y="240" font-size="13" font-weight="bold" fill="#1E64C8">Discoveries:</text>
                        <rect x="50" y="250" width="15" height="15" fill="#ffd700" stroke="#ff9800" stroke-width="1"/>
                        <text x="70" y="262" font-size="12" fill="#333">Upstream ORF (uORF)</text>
                        
                        <rect x="250" y="250" width="15" height="15" fill="#87ceeb" stroke="#2196F3" stroke-width="1"/>
                        <text x="270" y="262" font-size="12" fill="#333">Protein-coding lncRNA</text>
                        
                        <rect x="480" y="250" width="15" height="15" fill="#ffb6c1" stroke="#e91e63" stroke-width="1"/>
                        <text x="500" y="262" font-size="12" fill="#333">Alternative start codon</text>
                    </svg>
                </div>

                <p class="description">
                    Novel open reading frames (ORFs) are previously unannotated protein-coding sequences discovered through proteogenomic approaches. Traditional genome annotation relies heavily on computational predictions, which can miss short ORFs, alternative start codons, or protein-coding sequences in regions previously classified as non-coding.
                </p>

                <div class="subsection-title">Discovery Methods:</div>
                <p class="description">
                    Proteogenomics combines ribosome profiling (which shows where ribosomes are actively translating) with mass spectrometry to provide direct evidence of protein translation from novel ORFs. This approach has revealed that genomes are more complex than previously thought, with many small proteins and micropeptides being actively expressed.
                </p>

                <div class="key-points">
                    <strong>Types of Novel ORFs:</strong>
                    <ul>
                        <li><strong>Upstream ORFs (uORFs):</strong> Short coding sequences in the 5' UTR that regulate main ORF translation</li>
                        <li><strong>Downstream ORFs (dORFs):</strong> Additional coding sequences in the 3' UTR</li>
                        <li><strong>Long non-coding RNA (lncRNA) ORFs:</strong> Protein-coding capacity in presumed non-coding transcripts</li>
                        <li><strong>Short ORFs (sORFs):</strong> Micropeptides under 100 amino acids often missed by annotation pipelines</li>
                        <li><strong>Alternative translation start sites:</strong> Non-AUG start codons producing protein variants</li>
                    </ul>
                </div>

                <div class="applications">
                    <div class="applications-title">Research Impact:</div>
                    <ul>
                        <li><strong>Genome reannotation:</strong> Improving the accuracy of gene catalogs</li>
                        <li><strong>Functional genomics:</strong> Understanding previously unknown regulatory mechanisms</li>
                        <li><strong>Drug target discovery:</strong> Identifying new therapeutic targets among novel proteins</li>
                        <li><strong>Evolution studies:</strong> Understanding the birth and evolution of new genes</li>
                    </ul>
                </div>
            </div>

            <!-- 3. PTM Sites -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">3</div>
                    <span>Post-Translational Modification (PTM) Sites</span>
                </div>

                <div class="diagram-container">
                    <svg class="diagram-svg" viewBox="0 0 800 320" xmlns="http://www.w3.org/2000/svg">
                        <!-- Protein backbone -->
                        <text x="50" y="25" font-size="14" font-weight="bold" fill="#1E64C8">Protein with Multiple PTMs:</text>
                        
                        <!-- Main protein -->
                        <rect x="50" y="45" width="700" height="40" fill="#e8f4ff" stroke="#1E64C8" stroke-width="2" rx="5"/>
                        <text x="60" y="70" font-size="13" font-family="monospace" fill="#333">N-term───────────────────────────────────────C-term</text>
                        
                        <!-- Phosphorylation -->
                        <circle cx="150" cy="65" r="20" fill="#ff6b6b" opacity="0.7"/>
                        <text x="142" y="70" font-size="12" font-weight="bold" fill="white">P</text>
                        <path d="M 150 90 L 150 120" stroke="#ff6b6b" stroke-width="2"/>
                        <rect x="100" y="120" width="100" height="50" fill="#ffe6e6" stroke="#ff6b6b" stroke-width="2" rx="5"/>
                        <text x="108" y="138" font-size="11" font-weight="bold" fill="#ff6b6b">Phosphorylation</text>
                        <text x="110" y="152" font-size="10" fill="#333">Ser/Thr/Tyr</text>
                        <text x="110" y="164" font-size="9" fill="#666">Signal transduction</text>
                        
                        <!-- Acetylation -->
                        <circle cx="280" cy="65" r="20" fill="#4caf50" opacity="0.7"/>
                        <text x="272" y="70" font-size="12" font-weight="bold" fill="white">Ac</text>
                        <path d="M 280 90 L 280 120" stroke="#4caf50" stroke-width="2"/>
                        <rect x="230" y="120" width="100" height="50" fill="#e8f5e9" stroke="#4caf50" stroke-width="2" rx="5"/>
                        <text x="245" y="138" font-size="11" font-weight="bold" fill="#4caf50">Acetylation</text>
                        <text x="252" y="152" font-size="10" fill="#333">Lysine</text>
                        <text x="240" y="164" font-size="9" fill="#666">Gene regulation</text>
                        
                        <!-- Ubiquitination -->
                        <circle cx="410" cy="65" r="20" fill="#ff9800" opacity="0.7"/>
                        <text x="401" y="70" font-size="12" font-weight="bold" fill="white">Ub</text>
                        <path d="M 410 90 L 410 120" stroke="#ff9800" stroke-width="2"/>
                        <rect x="350" y="120" width="120" height="50" fill="#fff3e0" stroke="#ff9800" stroke-width="2" rx="5"/>
                        <text x="360" y="138" font-size="11" font-weight="bold" fill="#ff9800">Ubiquitination</text>
                        <text x="378" y="152" font-size="10" fill="#333">Lysine</text>
                        <text x="355" y="164" font-size="9" fill="#666">Protein degradation</text>
                        
                        <!-- Methylation -->
                        <circle cx="540" cy="65" r="20" fill="#9c27b0" opacity="0.7"/>
                        <text x="530" y="70" font-size="12" font-weight="bold" fill="white">Me</text>
                        <path d="M 540 90 L 540 120" stroke="#9c27b0" stroke-width="2"/>
                        <rect x="490" y="120" width="100" height="50" fill="#f3e5f5" stroke="#9c27b0" stroke-width="2" rx="5"/>
                        <text x="505" y="138" font-size="11" font-weight="bold" fill="#9c27b0">Methylation</text>
                        <text x="508" y="152" font-size="10" fill="#333">Lys/Arg</text>
                        <text x="497" y="164" font-size="9" fill="#666">Chromatin state</text>
                        
                        <!-- Glycosylation -->
                        <circle cx="670" cy="65" r="20" fill="#2196f3" opacity="0.7"/>
                        <text x="661" y="70" font-size="12" font-weight="bold" fill="white">Gly</text>
                        <path d="M 670 90 L 670 120" stroke="#2196f3" stroke-width="2"/>
                        <rect x="610" y="120" width="120" height="50" fill="#e3f2fd" stroke="#2196f3" stroke-width="2" rx="5"/>
                        <text x="623" y="138" font-size="11" font-weight="bold" fill="#2196f3">Glycosylation</text>
                        <text x="630" y="152" font-size="10" fill="#333">Asn/Ser/Thr</text>
                        <text x="620" y="164" font-size="9" fill="#666">Protein folding</text>
                        
                        <!-- Mass spec workflow -->
                        <text x="50" y="210" font-size="14" font-weight="bold" fill="#1E64C8">Proteogenomic PTM Mapping:</text>
                        
                        <!-- Workflow boxes -->
                        <rect x="50" y="225" width="140" height="60" fill="#fff" stroke="#1E64C8" stroke-width="2" rx="5"/>
                        <text x="70" y="245" font-size="12" fill="#333">Genomic Data</text>
                        <text x="60" y="260" font-size="10" fill="#666">Variant calling</text>
                        <text x="60" y="273" font-size="10" fill="#666">RNA-seq</text>
                        
                        <path d="M 195 255 L 225 255" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow)"/>
                        
                        <rect x="230" y="225" width="140" height="60" fill="#fff" stroke="#1E64C8" stroke-width="2" rx="5"/>
                        <text x="245" y="245" font-size="12" fill="#333">Custom Database</text>
                        <text x="240" y="260" font-size="10" fill="#666">Variant proteins</text>
                        <text x="240" y="273" font-size="10" fill="#666">+ PTM sites</text>
                        
                        <path d="M 375 255 L 405 255" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow)"/>
                        
                        <rect x="410" y="225" width="140" height="60" fill="#fff" stroke="#1E64C8" stroke-width="2" rx="5"/>
                        <text x="440" y="245" font-size="12" fill="#333">MS Analysis</text>
                        <text x="420" y="260" font-size="10" fill="#666">PTM enrichment</text>
                        <text x="420" y="273" font-size="10" fill="#666">LC-MS/MS</text>
                        
                        <path d="M 555 255 L 585 255" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow)"/>
                        
                        <rect x="590" y="225" width="140" height="60" fill="#fff" stroke="#1E64C8" stroke-width="2" rx="5"/>
                        <text x="610" y="245" font-size="12" fill="#333">PTM Mapping</text>
                        <text x="600" y="260" font-size="10" fill="#666">Site localization</text>
                        <text x="600" y="273" font-size="10" fill="#666">Quantification</text>
                        
                        <defs>
                            <marker id="arrow" markerWidth="10" markerHeight="10" refX="5" refY="3" orient="auto" markerUnits="strokeWidth">
                                <path d="M0,0 L0,6 L9,3 z" fill="#1E64C8" />
                            </marker>
                        </defs>
                    </svg>
                </div>

                <p class="description">
                    Post-translational modifications (PTMs) are chemical modifications to proteins after translation that dramatically expand protein functional diversity. Proteogenomics enhances PTM analysis by providing genomic context, allowing researchers to map PTM sites to specific protein variants, isoforms, and novel ORFs.
                </p>

                <div class="subsection-title">Major PTM Types and Functions:</div>
                <p class="description">
                    Over 400 different types of PTMs have been identified, but the most commonly studied include phosphorylation, acetylation, methylation, ubiquitination, and glycosylation. Each PTM type has distinct regulatory functions and can profoundly affect protein activity, localization, stability, and interactions.
                </p>

                <div class="key-points">
                    <strong>Proteogenomic Advantages for PTM Studies:</strong>
                    <ul>
                        <li><strong>Variant-specific PTMs:</strong> Identify how genetic variants create or eliminate PTM sites</li>
                        <li><strong>Isoform-specific modifications:</strong> Map PTMs to specific alternative splicing isoforms</li>
                        <li><strong>Novel site discovery:</strong> Find PTMs in previously unannotated proteins</li>
                        <li><strong>Functional context:</strong> Link PTMs to genomic features and disease variants</li>
                        <li><strong>Dynamic regulation:</strong> Track PTM changes across conditions or disease states</li>
                    </ul>
                </div>

                <div class="applications">
                    <div class="applications-title">Clinical and Research Applications:</div>
                    <ul>
                        <li><strong>Cancer biology:</strong> Aberrant PTM patterns as hallmarks of cancer</li>
                        <li><strong>Kinase inhibitor development:</strong> Targeting phosphorylation-dependent signaling</li>
                        <li><strong>Epigenetics:</strong> Understanding histone modifications and gene regulation</li>
                        <li><strong>Neurodegenerative diseases:</strong> Role of aberrant ubiquitination and phosphorylation</li>
                        <li><strong>Biomarker discovery:</strong> PTM signatures for disease diagnosis and prognosis</li>
                    </ul>
                </div>
            </div>

            <!-- 4. Protein Isoforms -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">4</div>
                    <span>Protein Isoforms from Alternative Splicing</span>
                </div>

                <div class="diagram-container">
                    <svg class="diagram-svg" viewBox="0 0 800 350" xmlns="http://www.w3.org/2000/svg">
                        <!-- Pre-mRNA -->
                        <text x="50" y="25" font-size="14" font-weight="bold" fill="#1E64C8">Pre-mRNA:</text>
                        
                        <!-- Exons and Introns -->
                        <rect x="50" y="40" width="80" height="30" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="72" y="60" font-size="12" fill="white">Exon 1</text>
                        
                        <line x1="135" y1="55" x2="175" y2="55" stroke="#999" stroke-width="2" stroke-dasharray="5,5"/>
                        <text x="145" y="50" font-size="10" fill="#999">Intron</text>
                        
                        <rect x="180" y="40" width="80" height="30" fill="#ffd700" stroke="#f57c00" stroke-width="2" rx="3"/>
                        <text x="202" y="60" font-size="12" fill="#333">Exon 2</text>
                        
                        <line x1="265" y1="55" x2="305" y2="55" stroke="#999" stroke-width="2" stroke-dasharray="5,5"/>
                        
                        <rect x="310" y="40" width="80" height="30" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="332" y="60" font-size="12" fill="white">Exon 3</text>
                        
                        <line x1="395" y1="55" x2="435" y2="55" stroke="#999" stroke-width="2" stroke-dasharray="5,5"/>
                        
                        <rect x="440" y="40" width="80" height="30" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="462" y="60" font-size="12" fill="white">Exon 4</text>
                        
                        <!-- Splicing arrows -->
                        <text x="300" y="105" font-size="13" font-weight="bold" fill="#1E64C8">Alternative Splicing</text>
                        <path d="M 250 115 L 200 145" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow2)"/>
                        <path d="M 300 115 L 300 145" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow2)"/>
                        <path d="M 350 115 L 400 145" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow2)"/>
                        
                        <!-- Isoform 1: All exons -->
                        <text x="50" y="175" font-size="12" font-weight="bold" fill="#2e7d32">Isoform 1 (Full-length):</text>
                        <rect x="50" y="185" width="60" height="25" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="64" y="202" font-size="10" fill="white">E1</text>
                        <rect x="115" y="185" width="60" height="25" fill="#ffd700" stroke="#f57c00" stroke-width="2" rx="3"/>
                        <text x="129" y="202" font-size="10" fill="#333">E2</text>
                        <rect x="180" y="185" width="60" height="25" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="194" y="202" font-size="10" fill="white">E3</text>
                        <rect x="245" y="185" width="60" height="25" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="259" y="202" font-size="10" fill="white">E4</text>
                        
                        <path d="M 310 197 L 340 197" stroke="#2e7d32" stroke-width="2" marker-end="url(#arrow2)"/>
                        <text x="350" y="202" font-size="11" fill="#333">Full function</text>
                        
                        <!-- Isoform 2: Exon skipping -->
                        <text x="50" y="240" font-size="12" font-weight="bold" fill="#f57c00">Isoform 2 (Exon 2 skipped):</text>
                        <rect x="50" y="250" width="60" height="25" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="64" y="267" font-size="10" fill="white">E1</text>
                        <rect x="115" y="250" width="60" height="25" fill="#e0e0e0" stroke="#999" stroke-width="2" stroke-dasharray="3,3" rx="3"/>
                        <text x="129" y="267" font-size="10" fill="#999">E2</text>
                        <rect x="180" y="250" width="60" height="25" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="194" y="267" font-size="10" fill="white">E3</text>
                        <rect x="245" y="250" width="60" height="25" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="259" y="267" font-size="10" fill="white">E4</text>
                        
                        <path d="M 310 262 L 340 262" stroke="#f57c00" stroke-width="2" marker-end="url(#arrow2)"/>
                        <text x="350" y="267" font-size="11" fill="#333">Altered domain</text>
                        
                        <!-- Isoform 3: Alternative 3' splice site -->
                        <text x="50" y="305" font-size="12" font-weight="bold" fill="#2196f3">Isoform 3 (Alternative splice):</text>
                        <rect x="50" y="315" width="60" height="25" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="64" y="332" font-size="10" fill="white">E1</text>
                        <rect x="115" y="315" width="40" height="25" fill="#87ceeb" stroke="#2196f3" stroke-width="2" rx="3"/>
                        <text x="124" y="332" font-size="9" fill="#333">E2*</text>
                        <rect x="160" y="315" width="60" height="25" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="174" y="332" font-size="10" fill="white">E3</text>
                        <rect x="225" y="315" width="60" height="25" fill="#4caf50" stroke="#2e7d32" stroke-width="2" rx="3"/>
                        <text x="239" y="332" font-size="10" fill="white">E4</text>
                        
                        <path d="M 290 327 L 320 327" stroke="#2196f3" stroke-width="2" marker-end="url(#arrow2)"/>
                        <text x="330" y="332" font-size="11" fill="#333">Truncated protein</text>
                        
                        <!-- Protein products -->
                        <rect x="530" y="160" width="240" height="180" fill="#f5f5f5" stroke="#1E64C8" stroke-width="2" rx="8"/>
                        <text x="550" y="180" font-size="13" font-weight="bold" fill="#1E64C8">Protein Isoforms:</text>
                        
                        <rect x="550" y="190" width="200" height="30" fill="#d4edda" stroke="#28a745" stroke-width="1" rx="3"/>
                        <text x="560" y="210" font-size="11" fill="#333">Full-length: 450 aa</text>
                        
                        <rect x="550" y="230" width="180" height="30" fill="#fff3cd" stroke="#ffc107" stroke-width="1" rx="3"/>
                        <text x="560" y="250" font-size="11" fill="#333">Shorter: 380 aa</text>
                        
                        <rect x="550" y="270" width="160" height="30" fill="#cce5ff" stroke="#2196f3" stroke-width="1" rx="3"/>
                        <text x="560" y="290" font-size="11" fill="#333">Variant: 390 aa</text>
                        
                        <text x="550" y="320" font-size="10" fill="#666" font-style="italic">Different functions,</text>
                        <text x="550" y="333" font-size="10" fill="#666" font-style="italic">localizations, stability</text>
                        
                        <defs>
                            <marker id="arrow2" markerWidth="10" markerHeight="10" refX="5" refY="3" orient="auto" markerUnits="strokeWidth">
                                <path d="M0,0 L0,6 L9,3 z" fill="#1E64C8" />
                            </marker>
                        </defs>
                    </svg>
                </div>

                <p class="description">
                    Alternative splicing is a fundamental mechanism that generates multiple protein isoforms from a single gene. It's estimated that over 95% of human multi-exon genes undergo alternative splicing, dramatically expanding proteomic diversity. Proteogenomics is essential for validating these isoforms at the protein level and understanding their functional consequences.
                </p>

                <div class="subsection-title">Types of Alternative Splicing:</div>
                <p class="description">
                    Alternative splicing can occur through several mechanisms: exon skipping (cassette exons), alternative 5' or 3' splice sites, intron retention, mutually exclusive exons, and alternative promoters or polyadenylation sites. Each mechanism produces distinct protein isoforms with potentially different functions, cellular localizations, or regulatory properties.
                </p>

                <div class="key-points">
                    <strong>Proteogenomic Challenges and Solutions:</strong>
                    <ul>
                        <li><strong>Isoform inference:</strong> RNA-seq identifies splice junctions; MS validates protein expression</li>
                        <li><strong>Isoform-specific peptides:</strong> Unique peptides that distinguish between isoforms</li>
                        <li><strong>Quantification:</strong> Measuring relative abundance of different isoforms</li>
                        <li><strong>Functional annotation:</strong> Linking isoforms to specific biological functions</li>
                        <li><strong>Disease relevance:</strong> Aberrant splicing in cancer and genetic diseases</li>
                    </ul>
                </div>

                <div class="applications">
                    <div class="applications-title">Biological and Clinical Significance:</div>
                    <ul>
                        <li><strong>Tissue-specific expression:</strong> Different isoforms predominate in different tissues</li>
                        <li><strong>Development and differentiation:</strong> Isoform switching during cell fate transitions</li>
                        <li><strong>Cancer diagnostics:</strong> Aberrant isoform ratios as cancer biomarkers</li>
                        <li><strong>Therapeutic targeting:</strong> Isoform-specific drugs for precision medicine</li>
                        <li><strong>Splice-modulating therapies:</strong> ASOs and small molecules to correct splicing defects</li>
                    </ul>
                </div>
            </div>

            <!-- 5. Neo-antigens -->
            <div class="detail-card">
                <div class="detail-header">
                    <div class="detail-number">5</div>
                    <span>Neo-antigens for Cancer Immunotherapy</span>
                </div>

                <div class="diagram-container">
                    <svg class="diagram-svg" viewBox="0 0 800 380" xmlns="http://www.w3.org/2000/svg">
                        <!-- Normal vs Tumor cell -->
                        <g id="normal-cell">
                            <circle cx="120" cy="80" r="60" fill="#90ee90" stroke="#28a745" stroke-width="3"/>
                            <text x="85" y="60" font-size="12" font-weight="bold" fill="#2e7d32">Normal Cell</text>
                            
                            <!-- MHC presentation -->
                            <rect x="100" y="75" width="40" height="15" fill="#fff" stroke="#2e7d32" stroke-width="2" rx="2"/>
                            <text x="105" y="86" font-size="9" fill="#333">MHC-I</text>
                            <rect x="107" y="63" width="12" height="12" fill="#4caf50" stroke="#2e7d32" stroke-width="1" rx="2"/>
                            <text x="109" y="72" font-size="8" fill="#fff">S</text>
                            <text x="95" y="110" font-size="9" fill="#2e7d32">Self-peptide</text>
                        </g>
                        
                        <!-- Arrow and mutation -->
                        <text x="185" y="75" font-size="12" font-weight="bold" fill="#ff6b6b">Mutation</text>
                        <path d="M 180 80 L 210 80" stroke="#ff6b6b" stroke-width="3" marker-end="url(#arrowred2)"/>
                        <text x="175" y="95" font-size="10" fill="#ff6b6b">DNA damage</text>
                        
                        <g id="tumor-cell">
                            <circle cx="280" cy="80" r="60" fill="#ffcccb" stroke="#ff6b6b" stroke-width="3"/>
                            <text x="250" y="60" font-size="12" font-weight="bold" fill="#c62828">Tumor Cell</text>
                            
                            <!-- MHC with neo-antigen -->
                            <rect x="260" y="75" width="40" height="15" fill="#fff" stroke="#ff6b6b" stroke-width="2" rx="2"/>
                            <text x="265" y="86" font-size="9" fill="#333">MHC-I</text>
                            <rect x="267" y="63" width="12" height="12" fill="#ff6b6b" stroke="#c62828" stroke-width="1" rx="2"/>
                            <text x="269" y="72" font-size="8" fill="#fff">N</text>
                            <text x="245" y="110" font-size="9" fill="#ff6b6b">Neo-antigen</text>
                        </g>
                        
                        <!-- T cell recognition -->
                        <g id="t-cell">
                            <ellipse cx="480" cy="80" rx="70" ry="50" fill="#87ceeb" stroke="#2196f3" stroke-width="3"/>
                            <text x="450" y="75" font-size="12" font-weight="bold" fill="#0d47a1">T Cell</text>
                            
                            <!-- TCR -->
                            <path d="M 410 75 L 390 75 L 385 70 L 385 80 L 390 75" fill="none" stroke="#0d47a1" stroke-width="2"/>
                            <circle cx="390" cy="75" r="8" fill="#fff" stroke="#0d47a1" stroke-width="2"/>
                            <text x="370" y="72" font-size="9" fill="#0d47a1">TCR</text>
                            
                            <text x="450" y="95" font-size="10" fill="#0d47a1">Activated</text>
                        </g>
                        
                        <!-- Connection arrows -->
                        <path d="M 345 80 L 405 80" stroke="#2196f3" stroke-width="2" marker-end="url(#arrowblue)"/>
                        <text x="360" y="75" font-size="10" fill="#2196f3">Recognition</text>
                        
                        <!-- Tumor killing -->
                        <path d="M 520 110 L 520 140" stroke="#ff6b6b" stroke-width="2" marker-end="url(#arrowred2)"/>
                        <text x="495" y="130" font-size="11" font-weight="bold" fill="#ff6b6b">Tumor Cell Death</text>
                        
                        <!-- Proteogenomics workflow -->
                        <text x="50" y="190" font-size="14" font-weight="bold" fill="#1E64C8">Neo-antigen Discovery Pipeline:</text>
                        
                        <!-- Step 1: Sequencing -->
                        <rect x="50" y="210" width="140" height="70" fill="#fff" stroke="#1E64C8" stroke-width="2" rx="5"/>
                        <text x="80" y="230" font-size="12" font-weight="bold" fill="#1E64C8">1. Sequencing</text>
                        <text x="60" y="248" font-size="10" fill="#333">• Tumor WES/WGS</text>
                        <text x="60" y="262" font-size="10" fill="#333">• Normal WES/WGS</text>
                        <text x="60" y="276" font-size="10" fill="#333">• Tumor RNA-seq</text>
                        
                        <path d="M 195 245 L 215 245" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow3)"/>
                        
                        <!-- Step 2: Variant calling -->
                        <rect x="220" y="210" width="140" height="70" fill="#fff" stroke="#1E64C8" stroke-width="2" rx="5"/>
                        <text x="235" y="230" font-size="12" font-weight="bold" fill="#1E64C8">2. Variant Calling</text>
                        <text x="230" y="248" font-size="10" fill="#333">• Somatic mutations</text>
                        <text x="230" y="262" font-size="10" fill="#333">• Expression filter</text>
                        <text x="230" y="276" font-size="10" fill="#333">• Clonality analysis</text>
                        
                        <path d="M 365 245 L 385 245" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow3)"/>
                        
                        <!-- Step 3: Prediction -->
                        <rect x="390" y="210" width="140" height="70" fill="#fff" stroke="#1E64C8" stroke-width="2" rx="5"/>
                        <text x="415" y="230" font-size="12" font-weight="bold" fill="#1E64C8">3. Prediction</text>
                        <text x="400" y="248" font-size="10" fill="#333">• MHC binding</text>
                        <text x="400" y="262" font-size="10" fill="#333">• Peptide processing</text>
                        <text x="400" y="276" font-size="10" fill="#333">• Immunogenicity</text>
                        
                        <path d="M 535 245 L 555 245" stroke="#1E64C8" stroke-width="2" marker-end="url(#arrow3)"/>
                        
                        <!-- Step 4: MS Validation -->
                        <rect x="560" y="210" width="140" height="70" fill="#fff" stroke="#ff9800" stroke-width="3" rx="5"/>
                        <text x="575" y="230" font-size="12" font-weight="bold" fill="#ff9800">4. MS Validation</text>
                        <text x="570" y="248" font-size="10" fill="#333">• Direct detection</text>
                        <text x="570" y="262" font-size="10" fill="#333">• Peptide library</text>
                        <text x="570" y="276" font-size="10" fill="#333">• Confirmation</text>
                        
                        <!-- Therapy options -->
                        <rect x="50" y="300" width="700" height="70" fill="#e8f5e9" stroke="#28a745" stroke-width="2" rx="8"/>
                        <text x="280" y="320" font-size="13" font-weight="bold" fill="#2e7d32">Therapeutic Applications</text>
                        
                        <g id="vaccine">
                            <rect x="70" y="330" width="180" height="30" fill="#fff" stroke="#28a745" stroke-width="2" rx="5"/>
                            <text x="90" y="350" font-size="11" fill="#333">Personalized Vaccines</text>
                        </g>
                        
                        <g id="tcr">
                            <rect x="270" y="330" width="180" height="30" fill="#fff" stroke="#28a745" stroke-width="2" rx="5"/>
                            <text x="285" y="350" font-size="11" fill="#333">Adoptive T Cell Therapy</text>
                        </g>
                        
                        <g id="checkpoint">
                            <rect x="470" y="330" width="200" height="30" fill="#fff" stroke="#28a745" stroke-width="2" rx="5"/>
                            <text x="485" y="350" font-size="11" fill="#333">Checkpoint Blockade + Neo</text>
                        </g>
                        
                        <defs>
                            <marker id="arrowred2" markerWidth="10" markerHeight="10" refX="5" refY="3" orient="auto" markerUnits="strokeWidth">
                                <path d="M0,0 L0,6 L9,3 z" fill="#ff6b6b" />
                            </marker>
                            <marker id="arrowblue" markerWidth="10" markerHeight="10" refX="5" refY="3" orient="auto" markerUnits="strokeWidth">
                                <path d="M0,0 L0,6 L9,3 z" fill="#2196f3" />
                            </marker>
                            <marker id="arrow3" markerWidth="10" markerHeight="10" refX="5" refY="3" orient="auto" markerUnits="strokeWidth">
                                <path d="M0,0 L0,6 L9,3 z" fill="#1E64C8" />
                            </marker>
                        </defs>
                    </svg>
                </div>

                <p class="description">
                    Neo-antigens are tumor-specific antigens arising from somatic mutations in cancer cells. These novel peptide sequences are not present in normal tissues, making them ideal targets for cancer immunotherapy. Proteogenomics plays a crucial role in neo-antigen discovery by combining genomic mutation data with proteomic validation to identify peptides that are actually presented on tumor cell surfaces.
                </p>

                <div class="subsection-title">The Neo-antigen Pipeline:</div>
                <p class="description">
                    Neo-antigen discovery begins with identifying somatic mutations through whole-exome or whole-genome sequencing of tumor and matched normal tissue. RNA-seq data filters for expressed mutations. Computational tools predict which mutant peptides will bind to the patient's specific MHC molecules and be presented on the cell surface. Critically, mass spectrometry provides direct experimental evidence that predicted neo-antigens are actually present on tumor cells.
                </p>

                <div class="key-points">
                    <strong>Types of Neo-antigens:</strong>
                    <ul>
                        <li><strong>SNV-derived:</strong> Point mutations creating single amino acid substitutions</li>
                        <li><strong>Indel-derived:</strong> Frameshift mutations generating completely novel sequences</li>
                        <li><strong>Gene fusion neo-antigens:</strong> Peptides spanning fusion breakpoints</li>
                        <li><strong>Splicing-derived:</strong> Aberrant splicing creating novel junctions</li>
                        <li><strong>Non-coding neo-antigens:</strong> Peptides from presumed non-coding regions</li>
                    </ul>
                </div>

                <div class="subsection-title">Why Mass Spectrometry Validation Matters:</div>
                <p class="description">
                    While computational prediction identifies thousands of potential neo-antigens, only a small fraction are actually processed, presented on MHC molecules, and detectable by mass spectrometry. MS validation reduces false positives, confirms peptide processing, validates MHC presentation, and prioritizes the most promising candidates for therapeutic development.
                </p>

                <div class="applications">
                    <div class="applications-title">Clinical Applications and Impact:</div>
                    <ul>
                        <li><strong>Personalized cancer vaccines:</strong> Patient-specific vaccines targeting validated neo-antigens</li>
                        <li><strong>CAR-T and TCR-T therapy:</strong> Engineering T cells to recognize specific neo-antigens</li>
                        <li><strong>Checkpoint inhibitor biomarkers:</strong> Tumor mutational burden and neo-antigen load predict response</li>
                        <li><strong>Combination strategies:</strong> Neo-antigen vaccines combined with checkpoint blockade</li>
                        <li><strong>Minimal residual disease monitoring:</strong> Tracking neo-antigen-specific immune responses</li>
                    </ul>
                </div>

                <div class="key-points">
                    <strong>Success Stories and Future Directions:</strong>
                    <ul>
                        <li>Clinical trials showing personalized neo-antigen vaccines can induce specific T cell responses</li>
                        <li>Improved response rates when combined with checkpoint inhibitors</li>
                        <li>Development of off-the-shelf shared neo-antigen libraries for common cancers</li>
                        <li>Integration of AI/ML for better neo-antigen prediction and prioritization</li>
                        <li>Expanding beyond MHC-I to MHC-II neo-antigens for CD4+ T cell activation</li>
                    </ul>
                </div>
            </div>

        </div>
    </div>
</body>
</html>